Breast carcinoma
MONDO:0004989A carcinoma that arises from epithelial cells of the breast
Also known as: breast cancer, breast cancer, NOS, cancer of breast, cancer of the breast, cancer, breast, breast carcinoma, carcinoma of breast, carcinoma of the breast
5353 clinical trials for this condition and its sub-types, 665 tagged with Breast carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Breast carcinoma
-
Breast carcinoma by gene expression profile 0 trials · 1,791 incl. sub-types
8 sub-types
- Her2-receptor negative breast cancer 241 trials · 1,363 incl. sub-types Sub-types →
- Estrogen-receptor positive breast cancer 183 trials · 773 incl. sub-types Sub-types →
- Estrogen-receptor negative breast cancer 24 trials · 707 incl. sub-types Sub-types →
- Progesterone-receptor negative breast cancer 3 trials · 705 incl. sub-types Sub-types →
- Progesterone-receptor positive breast cancer 16 trials · 662 incl. sub-types Sub-types →
- HER2 positive breast carcinoma 408 trials · 427 incl. sub-types Sub-types →
- Breast tumor luminal A or B 6 trials · 15 incl. sub-types Sub-types →
- Normal breast-like subtype of breast carcinoma 0 trials
-
Invasive breast carcinoma 325 trials · 413 incl. sub-types
11 sub-types
- Invasive ductal breast carcinoma 41 trials · 48 incl. sub-types Sub-types →
- Invasive lobular breast carcinoma 30 trials
- Inflammatory breast carcinoma 29 trials
- Metaplastic breast carcinoma 4 trials · 5 incl. sub-types Sub-types →
- Adenoid cystic breast carcinoma 0 trials
- Breast large cell neuroendocrine carcinoma 0 trials
- Malignant breast myoepithelioma 0 trials
- Mucoepidermoid breast carcinoma 0 trials
- Oncocytic breast carcinoma 0 trials
- Sebaceous breast carcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
-
Breast adenocarcinoma 36 trials · 279 incl. sub-types
13 sub-types
- Breast ductal adenocarcinoma 19 trials · 192 incl. sub-types Sub-types →
- Breast lobular carcinoma 13 trials · 34 incl. sub-types Sub-types →
- Inflammatory breast carcinoma 29 trials
- Lobular breast carcinoma in situ 27 trials
- Mixed lobular and ductal breast carcinoma 1 trial Sub-types →
- Adenoid cystic breast carcinoma 0 trials
- Breast malignant eccrine spiradenoma 0 trials
- Breast mucinous cystadenocarcinoma 0 trials
- Mammary Paget disease 0 trials Sub-types →
- Mucoepidermoid breast carcinoma 0 trials
- Oncocytic breast carcinoma 0 trials
- Sebaceous breast carcinoma 0 trials
- Signet ring cell breast carcinoma 0 trials
-
Breast carcinoma in situ 76 trials · 204 incl. sub-types
4 sub-types
- Ductal breast carcinoma in situ 152 trials Sub-types →
- Lobular neoplasia 4 trials · 30 incl. sub-types Sub-types →
- Ductal breast carcinoma in situ and lobular carcinoma in situ 1 trial
- Breast apocrine carcinoma in situ 0 trials
-
Female breast carcinoma 138 trials
7 sub-types
- Female breast axillary tail cancer 0 trials
- Female breast central part cancer 0 trials
- Female breast lower-inner quadrant cancer 0 trials
- Female breast lower-outer quadrant cancer 0 trials
- Female breast nipple and areola cancer 0 trials
- Female breast upper-inner quadrant cancer 0 trials
- Female breast upper-outer quadrant cancer 0 trials
-
Male breast carcinoma 22 trials
-
Hereditary breast carcinoma 10 trials
1 sub-type
-
Bilateral breast carcinoma 6 trials · 9 incl. sub-types
2 sub-types
- Synchronous bilateral breast carcinoma 3 trials
- Lipid-rich breast carcinoma 0 trials
-
Hormone-resistant breast carcinoma 5 trials
-
Sporadic breast cancer 2 trials
-
Ehrlich tumor carcinoma 0 trials
-
Cribriform carcinoma of breast 0 trials
1 sub-type
-
Nipple carcinoma 0 trials
2 sub-types
- Paget disease of the nipple 0 trials
- Nipple duct carcinoma 0 trials
Most studied deeper sub-types
-
New pill shows promise in early trial for Hard-to-Treat breast cancer
Disease control Stopped earlyThis early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…
Phase 1 • Sponsor: Boundless Bio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can an immune booster help chemotherapy fight metastatic breast cancer?
Disease control Stopped earlyThis trial tests whether adding an experimental immunotherapy called eftilagimod alpha to standard chemotherapy (paclitaxel) can help people with HER2-negative metastatic breast cancer live longer. The study first finds the best dose of eftilagimod alpha, then compares the combin…
Phase 2/3 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Could an extra antibody slow HER2+ breast cancer spread?
Disease control Stopped earlyThis trial investigates whether adding bevacizumab (Avastin) to standard first-line chemotherapy plus trastuzumab (Herceptin) helps people with HER2-positive metastatic breast cancer. Participants receive either bevacizumab or a placebo alongside their regular treatment. The main…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Breast cancer drug showdown: which CDK4/6 inhibitor works best?
Disease control Stopped earlyThis phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…
Phase 3 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental combo targets metastatic breast cancer
Disease control Stopped earlyThis early-stage study tested the safety and best dose of combining the drugs RAD001 and docetaxel in 15 people with metastatic breast cancer. The goal was to find a dose that is tolerable while potentially controlling the disease. The study was terminated early, so results are l…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy combo tested for aggressive breast cancer – trial stopped early
Disease control Stopped earlyThis phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and HER2-targeted therapy could help people with HER2-positive breast cancer that has spread. The study enrolled 190 participants but was terminated early, so the full results ar…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Brain cancer trial halted early: can Memory-Sparing radiation help when tumors return?
Disease control Stopped earlyThis phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control Stopped earlyThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Tailored cancer therapy put to the test
Disease control Stopped earlyThis study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …
Phase 2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Common diabetes and acne drugs tested against cancer
Disease control Stopped earlyThis phase 2 trial tested whether combining metformin (a diabetes drug) with doxycycline (an antibiotic) could help treat localized breast and uterine cancers. The study enrolled 29 people who were scheduled for surgery. Researchers looked at changes in certain proteins in the tu…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Pazopanib dose hunt in frail seniors halted early
Disease control Stopped earlyThis phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…
Phase 1 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Promising breast cancer drug tested in resistant patients – but trial cut short
Disease control Stopped earlyThis phase 2 trial aimed to see if trastuzumab deruxtecan (Enhertu) could help people with HER2-positive breast cancer that had spread and did not respond to standard first-line therapy. Only 2 participants were enrolled before the study was terminated early, so the results are v…
Phase 2 • Sponsor: Spanish Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Experimental chemo drug tested for advanced breast cancer
Disease control Stopped earlyThis phase 2 trial tested the chemotherapy drug ixabepilone in 13 patients with metastatic breast cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow the disease. The study was terminated early, so the full result…
Phase 2 • Sponsor: Allarity Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Promising combo for tough breast cancers hits early hurdle
Disease control Stopped earlyThis early-phase trial tested a combination of targeted drugs (neratinib, pertuzumab, trastuzumab) and chemotherapy (paclitaxel, doxorubicin, cyclophosphamide) in 34 people with advanced or inflammatory breast cancer. The goal was to find the best dose and see if the combo could …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can sound waves boost immunotherapy in breast cancer?
Disease control Stopped earlyThis early study tested combining high-intensity focused ultrasound (HIFU) with the immunotherapy drug pembrolizumab (Keytruda) in 13 people with metastatic breast cancer. The goal was to see if the ultrasound could help the immune system better recognize and attack tumors. The t…
Phase 1 • Sponsor: Patrick Dillon, MD • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control Stopped earlyThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Phase 1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Heating tumors plus drug shows promise in early breast cancer trial
Disease control Stopped earlyThis early-phase trial tested a combination of hyperthermia (heating the tumor area) and the drug olaparib in 3 patients with breast cancer that had returned on the chest wall. The goal was to see if the combination was safe and could slow tumor growth. The study was terminated e…
Phase 1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Targeted drug combo shows promise for rare breast cancer subtype
Disease control Stopped earlyThis phase 2 trial tested the drug futibatinib (TAS-120), alone or with the hormone therapy fulvestrant, in people with metastatic breast cancer that has specific FGFR gene changes. The study aimed to see if the treatment could shrink tumors or slow cancer growth. However, the tr…
Phase 2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase 1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Promising combo study for HER2+ breast cancer halted early
Disease control Stopped earlyThis study looked at adding a drug called copanlisib to standard targeted therapy (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that had spread and had specific gene changes (PIK3CA or PTEN). The goal was to see if the combination was safe and could hel…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug targets Hard-to-Treat cancers in new trial
Disease control Stopped earlyThis phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…
Phase 2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Exercise program targets metabolic risks in cancer survivors
Disease control Stopped earlyThis study looked at whether a specific type of exercise, combining aerobic and resistance training in short bursts, could improve metabolic health in overweight or obese breast and prostate cancer survivors who had finished treatment. The goal was to reduce insulin resistance an…
Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New scan could predict hormone therapy success in breast cancer
Diagnosis Stopped earlyThis study tested a special PET/CT scan using a radioactive tracer called FES to see estrogen receptor activity in women with advanced, hormone-resistant breast cancer. The goal was to see if the scan could predict how well a new hormone therapy would work. Only 6 people were enr…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
Brain radiation for breast cancer: prevention study halted early
Prevention Stopped earlyThis study looked at whether giving radiation to the brain could prevent cancer from spreading there in people with HER2-positive breast cancer that had already spread to other organs. Participants were receiving trastuzumab (Herceptin) plus chemotherapy. The study was stopped ea…
Phase 3 • Sponsor: Centre Oscar Lambret • Aim: Prevention
Last updated Sep 19, 2026 00:00 UTC
-
Breast cancer prevention study halted: tamoxifen pill vs. gel tested
Prevention Stopped earlyThis study aimed to see if a tamoxifen skin gel could work as well as the pill to lower breast cancer risk in women with certain high-risk breast conditions. The trial enrolled 65 women and compared short-term changes in breast tissue. However, the study was terminated early, so …
Phase 2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Brain-Sensing headband tested to ease cancer Survivors' anxiety
Symptom relief Stopped earlyThis pilot study tests whether a wearable EEG headband (MUSE-S) that guides meditation can help breast cancer survivors who struggle with anxiety and insomnia. Twenty participants will use the headband at home, and researchers will track how often they use it and whether it impro…
Early phase 1 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Could a simple TENS device ease chemo nerve pain?
Symptom relief Stopped earlyThis trial tested whether a TENS device, which sends mild electrical pulses to the skin, can help relieve nerve pain caused by chemotherapy in early-stage breast cancer patients. The study enrolled 17 people who were having taxane chemotherapy and had at least mild nerve pain in …
Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can meal timing protect your brain during cancer treatment?
Symptom relief Stopped earlyThis study tested a text-message-based diet program called Txt4fasting for people with breast or lung cancer that spread to the brain. The goal was to see if eating only during certain hours could reduce thinking and memory problems after radiation. Only 1 person enrolled before …
Sponsor: Thomas Jefferson University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Why did women skip a breast cancer trial? COVID money woes may be key
Knowledge-focused Stopped earlyThis study looked at whether COVID-19 caused more financial hardship for Women of Color compared to other women who decided not to join a breast cancer screening trial. Researchers surveyed 14 women about job loss, income drops, and housing or food insecurity. The goal was to und…
Sponsor: Eastern Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can community storytelling boost breast cancer screening in rural areas?
Knowledge-focused Stopped earlyThis study tests whether community health forums called WE-CARE can help more rural and low-income women get screened for breast cancer and join clinical trials. The forums include educational sessions, survivor storytelling, and patient navigation to address barriers. Researcher…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Gene study may explain why some breast cancers resist hormone therapy
Knowledge-focused Stopped earlyThis study looked at whether a specific gene mutation (HSD3B1) changes how well the hormone therapy letrozole works in postmenopausal women with early-stage, hormone-sensitive breast cancer. Researchers measured changes in tumor markers before and after treatment. The trial was e…
Phase 4 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Immune system secrets in advanced breast cancer under the microscope
Knowledge-focused Stopped earlyThis observational study aimed to measure different types of immune cells in women with advanced breast cancer that has spread. Researchers collected blood and leftover tumor samples to see how these cells change over time. The study was terminated early, so only a small number o…
Sponsor: Spanish Breast Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Genetic test aims to improve breast cancer decisions for black and hispanic women
Knowledge-focused Stopped earlyThis study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about screening and prevention. Researchers enrolled 19 women at higher risk for breast cancer. The stu…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Virtual reality could help measure and treat cancer pain, study suggests
Knowledge-focused Stopped earlyThis study explored whether a wearable brain scanner (fNIRS) could objectively measure pain in cancer patients and survivors. It also tested if virtual reality (VR) relaxation could help reduce pain. The study included 106 participants, including healthy volunteers and cancer pat…
Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New MRI technique aims to detect hidden heart harm from cancer radiation
Knowledge-focused Stopped earlyThis early-phase study tested whether a special MRI technique could detect early signs of heart damage caused by radiation therapy in people with thoracic or left-sided breast cancer. The approach used an injected substance (hyperpolarized pyruvate) to measure changes in heart ce…
Early phase 1 • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC